Rising Health Report w/ Maria
@risinghealthreport • 14,500 subscribers
Videos
Compounding pharmacy prescriptions for compounded tirzepatide and semaglutide are supposed to be personalized. Two new documents question whether they are. FDA's September 18 warning letter to Empower Pharmacy says the "significant difference" notes on prescriptions showed up word for word across many orders. FDA said they may have been pre-generated for prescribers to pick from a menu. On September 25, a federal judge in Lilly's case against Strive Pharmacy ordered Strive to turn over its tirzepatide regulator records. The judge cited a 2025 Arizona Board of Pharmacy inspection that found identical wording in the clinical justifications for "personalized" prescriptions. The case isn't decided. A warning letter isn't a recall. Talk to your prescriber before changing anything. #compoundingpharmacy #glp1community #pharmacy #healthnews #bigpharma
Rising Health Report w/ Maria19,800 просмотров • 1 месяц назад
Больше нет контента для загрузки
